Archives: 2019-04-05

WHO WE ARE

Dr. Pier Maria Fornasari is Scientific Director and CEO of REGENHEALTHSOLUTIONS.Degree in Medicine and Surgery, specialized in Internal Medicine, Clinic and Laboratory Haematology, Anaesthesiology and Health Statistics. Since 1976 researcher at the University of Pavia on extracorporeal blood manipulation in critical patients. Since 1995 to 2015, Director of the Transfusion Medicine/ Musculoskeletal Cell and Tissue

Read More


RESTORE Consortium – CURING CHRONIC DISEASES BY “LIVING DRUGS”

OVERVIEW Shifting from treating symptoms to curing chronic diseases by making the transformative promise of Advanced Therapies a reality for the benefit of patients and society and by making Europe a spearhead of Advanced Therapies in Science,Clinics and Biomedical Industry, that is the vision of the international project RESTORE Health by Advanced Therapies, coordinated by

Read More


Artificial intelligence helps to better assess treatment response of brain tumors

A team from Heidelberg University Hospital and the German Cancer Research Centre has developed a new method for the automated image analysis of brain tumors. In their recent publication, the authors show that machine learning methods carefully trained on standard magnetic resonance imaging (MRI) are more reliable and precise than established radiological methods in the

Read More


FDA is investigating reports of 35 cases of seizures after vaping

The FDA has become aware that some people who use e-cigarettes have experienced seizures, with most reports involving youth or young adult users. Seizures or convulsions are known potential side effects of nicotine toxicity and have been reported in the scientific literature in relation to intentional or accidental swallowing of e-liquid. However, a recent uptick in voluntary

Read More


Researchers conduct largest study of childhood cancer after conception by IVF

In the past three decades, in vitro fertilization (IVF) has gone from an experimental procedure to being more common. Pregnancies enabled by IVF frequently have more difficulties, with children born earlier and smaller even among singleton births. University of Minnesota researchers conducted the largest study of childhood cancer after conception by IVF to date. This

Read More


CAR T Cell Toxicity

By late 2018, 2 chimeric antigen receptor T (CAR T) cell products have been approved by US and European regulatory authorities. Tisagenlecleucel (Kymriah, Novartis) is indicated in the treatment of patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse (ELIANA trial), or

Read More